title: Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis.
abstract: Unilateral pyelonephritis was induced in 50 rabbits by injecting Escherichia coli (minimum inhibitory concentration of tobramycin 0.25 mg/l) into the left kidney and by obstructing the ureter temporarily. Tobramycin treatment (daily dose 10 mg/kg) was started 4 days after surgery, either in a single daily dose or in 3 divided doses at 8 h intervals, for 2, 3, 5, 7 or 10 days. Comparison of bacteriology, renal morphology, and renal functions (BUN, serum creatinine, alanine aminopeptidase, N-acetyl-beta-D-glucosaminidase, cathepsin B, sphingomyelinase) suggests better efficacy and renal tolerance of the single daily dose regimen in the treatment of experimental acute pyelonephritis.
mesh_terms: D000118:Acetylglucosaminidase / Q000378:metabolism; D000626:Aminopeptidases / Q000378:metabolism; D000818:Animals; D018826:CD13 Antigens; D002401:Cathepsin B / Q000378:metabolism; D004334:Drug Administration Schedule; D007668:Kidney / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology; D008297:Male; D011704:Pyelonephritis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011817:Rabbits; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism; D014031:Tobramycin / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D013108:Sphingomyelin Phosphodiesterase; D000118:Acetylglucosaminidase; D000626:Aminopeptidases; D018826:CD13 Antigens; D002401:Cathepsin B; D014031:Tobramycin